Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is of great interest to determine which biomarkers should be combined to ac...

Full description

Bibliographic Details
Main Authors:	Julie Ottoy, Ellis Niemantsverdriet, Jeroen Verhaeghe, Ellen De Roeck, Hanne Struyfs, Charisse Somers, Leonie wyffels, Sarah Ceyssens, Sara Van Mossevelde, Tobi Van den Bossche, Christine Van Broeckhoven, Annemie Ribbens, Maria Bjerke, Sigrid Stroobants, Sebastiaan Engelborghs, Steven Staelens
Format:	Article
Language:	English
Published:	Elsevier 2019-01-01
Series:	NeuroImage: Clinical
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213158219301214

Internet

http://www.sciencedirect.com/science/article/pii/S2213158219301214

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging

Internet

Similar Items